<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10970685</article-id><article-id pub-id-type="pmc">2374680</article-id><article-id pub-id-type="pii">6691397</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1397</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primaryon-small-cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moriya</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Takiguchi</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tabeta</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kimura</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nagao</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kuriyama</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Chest Medicine, Chiba University School of Medicine, Chiba, Japan</aff><aff id="aff2"><label>2</label>Department of Chest Medicine, Funabashi Medical Center, Funabashi, Japan</aff><aff id="aff3"><label>3</label>Health Sciences Center, Chiba University, Chiba, Japan</aff><pub-date pub-type="epub"><day>04</day><month>09</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2000</year></pub-date><volume>83</volume><issue>7</issue><fpage>858</fpage><lpage>862</lpage><history><date date-type="received"><day>07</day><month>12</month><year>1999</year></date><date date-type="rev-recd"><day>26</day><month>06</month><year>2000</year></date><date date-type="accepted"><day>04</day><month>07</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Malignant pericarditis, when associated with massive pericardial effusion, presents a critical condition in lung cancer patients. Because this condition often arises in terminally ill patients, intensive therapy such as multi-drug combination chemotherapy is rarely appropriate. This study evaluated the clinical relevance of intrapericardial administration of carboplatin for controlling malignant pericardial effusions associated with non-small-cell lung carcinoma (NSCLC). The method used for 10 eligible patients consisted of draining the pericardial effusion and infusing 300 mg/body of carboplatin in 50 ml of saline through an in-place catheter into the pericardial space and clamping the catheter for 40 min. Nine of the 10 patients showed satisfactory results, and 8 experienced complete regression of the effusion. No major or minor adverse effects were observed. Pharmacokinetics analysis revealed that the concentration of free platinum in the pericardial fluid was very high while that of total platinum in the circulating plasma was very low, assuring the usefulness of the intrapericardial instillation of carboplatin in terminally ill patients for controlling malignant pericardial effusion when the systemic delivery of cytotoxic agents is inappropriate. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>cardiac tamponade</kwd><kwd>pericardial effusion</kwd><kwd>malignant pericarditis</kwd><kwd>lung cancer</kwd><kwd>carboplatin</kwd><kwd>pharmacokinetics</kwd></kwd-group></article-meta></front></article>


